# Myriad Genetics **Type:** venture **Status:** Draft **Confidence:** Medium **Focus:** molecular diagnostics, hereditary cancer, oncology genomics, reproductive health, precision medicine **Stage:** Public (NASDAQ: MYGN) **Location:** Salt Lake City, UT **Updated:** 2026-06-19 **Needs-reviewed:** 2026-06-19 **Hero:** https://picsum.photos/seed/myriad-genetics-diagnostics-slc-2026/1600/1100 **Pull:** *Thirty years of clinical genetic testing from Salt Lake City — hereditary cancer, oncology genomics, reproductive health, and beyond.* **Relates:** cites [Official Website: Myriad Genetics](myriad-genetics-official-website.md) ## Summary Myriad Genetics is a publicly traded molecular diagnostics company headquartered in Salt Lake City, Utah. It develops and commercializes genetic and genomic tests across hereditary cancer risk, reproductive health, oncology, urology, and mental health pharmacogenomics. The company's public website positions Myriad as a long-running clinical genomics lab that partners with providers to detect risk, guide treatment, and prevent disease. For the Great Work wiki, Myriad matters both as a current Utah employer in precision medicine and as the institution that grew out of Utah's hereditary-cancer research environment — the founding BRCA sequencing and patent story is documented separately on the work page. ## Impact Myriad helped establish that inherited cancer risk could be tested routinely in clinical care. Today its impact is measured through deployed laboratory tests: hereditary cancer panels that inform screening and prevention decisions, tumor genomic profiling that can surface therapy-linked biomarkers, reproductive-health screens for expectant parents, and prostate-cancer tests that aim to clarify aggressiveness. At Utah scale, Myriad remains one of the state's largest life-sciences employers and a visible anchor of the Wasatch Front genomics cluster alongside university research institutes, ARUP Laboratories, and consumer-genomics companies. ## What They Are Building Myriad's current portfolio spans five public-facing health areas: - **Hereditary cancer risk** — multi-cancer germline panels (the site references tests covering 11 hereditary cancers, including MyRisk). - **Oncology** — germline and tumor genomic tests intended to support screening, treatment selection, and survivorship decisions. - **Reproductive health** — carrier screening, prenatal chromosomal testing, and early fetal-sex determination products. - **Urology** — Prolaris and related prostate-cancer tests; the site highlights newer Prolaris + AI capabilities combining genomics with digital pathology. - **Mental health** — pharmacogenomic testing to inform antidepressant and related medication selection. The harder-to-see product is the accumulated variant-interpretation, reporting, and laboratory infrastructure behind those menus — plus the payer, provider-education, and health-system integration work required to keep tests in clinical use at scale. ## What They Need Now Likely needs include molecular biologists, bioinformatics engineers, clinical laboratory scientists, variant-curation specialists, regulatory and quality professionals familiar with laboratory-developed tests, health-system partnership managers, and product leaders who can translate genomics into clinician-friendly reports. For talent matching, Myriad suits scientists and operators who want clinically deployed precision medicine in Utah rather than relocating to Boston or the Bay Area — with the caveat that public-company diagnostics businesses carry payer, competition, and quarterly-volume dynamics that differ from early-stage biotech. ## Who Could Help Useful helpers include FDA and CLIA regulatory counsel, health-system genomics program leaders, payer-relations advisors, clinical laboratory automation experts, and commercial partners that extend test distribution into hospital networks. ## Utah Context Myriad was founded in Salt Lake City in 1991 and remains headquartered there. Its origins connect to University of Utah human genetics research and the state's unusual genealogical and medical-record infrastructure; see [Myriad Genetics BRCA Sequencing and Testing](myriad-genetics-brca.md) for that historical work story rather than repeating it here. In the present tense, Myriad is part of Utah's "Genome Valley" cluster — a concentration of genomics, bioinformatics, and diagnostics activity anchored by the University of Utah, ARUP, and neighboring ventures such as [BioFire Diagnostics](biofire-diagnostics.md) and [Ancestry](ancestry.md). ## Evidence - [Official Website: Myriad Genetics](myriad-genetics-official-website.md) ## See Also - [Myriad Genetics BRCA Sequencing and Testing](myriad-genetics-brca.md) - [Utah Population Database](utah-population-database.md) - [BioFire Diagnostics](biofire-diagnostics.md) - [Huntsman Cancer Institute](huntsman-cancer-institute.md) ## Open Questions - Current employee count, test volume, and revenue should be verified against SEC filings or investor materials before use in recommendations. - How competitive Myriad's oncology and liquid-biopsy offerings are versus peers such as Natera and Guardant is not established from the official website alone. - CEO and strategy transitions in recent years deserve a sourced leadership timeline if this page is promoted beyond Draft. - Imagery is a deterministic placeholder; swap for a license-cleared laboratory, product, or facilities photograph when available.